| Title | Venue | Year | Impact | Source |
| 4651 | eP217: Ophthalmology genetics clinic in the times of COVID-19: A hybrid model | Genet Med | 2022 | | CORD-19 |
| 4652 | eP491: COVID-19 and clinical genomics: A Detroit community hospital's telehealth experience | Genet Med | 2022 | | CORD-19 |
| 4653 | eP294: Return of genome sequencing results in ostensibly healthy COVID-19 positive individuals: GENCOV Study Canada | Genet Med | 2022 | | CORD-19 |
| 4654 | eP384: Clinical, epidemiological and genetic characteristics of children diagnosed with Multisystem Inflammatory Syndrome (MIS-C) in Kuwait Introduction: The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has resulted in an ongoing vicious pandemic. COVID-19 has a wide range of clinical outcomes ranging from no clinical symptoms to severe respiratory disease and death. Disease severity has been linked to old age and other co-morbidities. In children and infants, the infection has typically a milder and often asymptomatic course. However, Multisystem Inflammatory Syndrome in Children (MIS-C) has been recognized as a pediatric complication of severe acute respiratory syndrome coronavirus-2 infections. It is a state of hyperinflammation that typically presents 4-6 weeks after SARS-CoV-2 acute infection with high fever, organ dysfunction, and raised inflammatory markers leading to multiorgan failure and shock. Family clusters of MIS-C have been reported suggesting heritable traits predisposing to severe infection. The underlying cause of phenotypic heterogeneity, susceptibility, and disease severity among affected individuals is still unclear. It has been thought that both viral and host genetic variations could be probable factors influencing the disease severity and susceptibility. To this end, we have studied the clinical and genetic characteristics of children with MIS-C in Kuwait. Utilizing 28 large kindreds with familial MIS-C clustering, we report, here, the preliminary results obtained from three families. Methods: Children aged ≤ 12 years who met the World Health Organization (WHO) MIS-C diagnostic criteria were identified from the national Pediatric COVID-19 Registry in Kuwait (PCR-Q8). Detailed demographic and clinical phenotype data were obtained from medical charts. All subjects and their families were invited for blood molecular genetic testing. Genetic analysis using genome sequencing at 30x depth has been performed on the affected individuals and their parents. In this , we present preliminary results from three families. Results: Sixty-seven children with MIS-C were identified in the period between April 2020 and October 2021. So far, molecular genetic testing was performed on 28 subjects and their biological parents. Genetic analysis (genome sequencing) of 3 families was completed. All of the three children were previously healthy, non-obese, with no known co-morbidities, and no family history of MIS-C. They all had evidence of recent SARS-CoV-2 infection (positive RT-PCR result and positive IgG antibody detection). One child aged 9 years developed myocarditis as a complication of MIS-C. He presented with hypotension, hemodynamic instability, and required inotropic support. All three kids have fully recovered after receiving respiratory support in the Pediatric Intensive Care Unit (PICU). Consanguinity was observed in two families. Probands harbored various homozygous variants in the BTNL8, IL17RA, and IRS4 genes will be presented and discussed. Conclusion: This is the first study to review the demographic, clinical, epidemiological, and genetic characteristics of children with MIS-C in Kuwait. Although familial clustering of severe COVID-19 infection has not been observed in our cohort, our data shows that utilizing a family-based study allows for significant enrichment for homozygous genetic variants that may impact our understanding of MIS-C. | Genet Med | 2022 | | CORD-19 |
| 4655 | eP510: High patient satisfaction with specialty pediatric services using telemedicine during the COVID-19 pandemic | Genet Med | 2022 | | CORD-19 |
| 4656 | eP321: Extending and adapting the functions of genetic laboratories in the continuing COVID pandemic-challenges and successes | Genet Med | 2022 | | CORD-19 |
| 4657 | eP411: Tackling the COVID-19 pandemic by utilizing next generation sequencing technologies | Genet Med | 2022 | | CORD-19 |
| 4658 | eP187: Decentralization of clinical trials in the era of COVID-19: Implications for rare disease trials | Genet Med | 2022 | | CORD-19 |
| 4659 | eP484: Scaling a high throughput next generation sequencing laboratory for community surveillance of SARS-CoV-2 viral variants during the public health crisis | Genet Med | 2022 | | CORD-19 |
| 4660 | eP490: A united front on tackling a pandemic-the true value of industry and government partnerships Introduction: The emergence of the SARS-CoV-2 virus, the cause of the COVID-19 pandemic, in late 2019 put every country on high alert and led to major changes in global diagnostic testing capability in infectious disease. From the outset it was apparent that local health authorities were under-prepared and under-staffed to cope with the rapid onset and spread of the disease. Demand for SAR-CoV-2 testing soared, highlighting the limitations of capacity in existing infectious disease laboratories along with requests from governments to support growing testing need. We partnered with US and UK Governments to establish, supply, staff and operate three large-scale, high-throughput SARS-CoV-2 testing facilities. These were ultimately established in Valencia, CA, offering testing of up to 150k samples per day, and in Loughborough and Newport, UK, offering a combined testing of up to 70k samples per day. The biggest challenge faced globally was the unprecedented scale of testing required and the timeframe to deliver a reliable and sensitive high-throughput assay. The benefits of industry and government partnerships become evident along with having a dedicated supply chain to feed the reagent and consumable needs for high-throughput testing as well as a highly accurate test with a fast turnaround time. Experts from multiple divisions, including R&D, Genomics, Enterprise, and regional centres were bought into the project, resulting in the establishment of SARS-CoV-2 testing within the three facilities in approximately eight weeks. Clinical testing experts in high-throughput, newborn screening, and rare disease testing, built molecular testing pipelines for the facilities based around the use of real-time polymerase chain reaction (RT-PCR) assays and sequencing. Laboratories were setup to meet the requirements set by various regulatory and accreditation agencies such as Clinical Laboratory Improvement Amendments, College of American Pathologies, the UK National Health Service validation group and ISO15189. Methods: Underpinning the testing was the massive IT and bioinformatics effort to enable reporting of the testing outcomes to the relevant authorities. We were able to deploy a novel LIMS system that is used throughout the laboratories to maintain sample chain of custody from arrival at the facility to reporting of results and incorporating interpretive software to support clinical interpretation of the resulting RT-PCR data. The LIMS systems are constantly undergoing improvement to support interpretation and troubleshooting. Local experts in clinical interpretation and reporting were onboarded to augment data analysis and ensure high-quality and reliable reporting whilst ensuring that clinical governance remains at the centre of all activities. Results: Before any SARS-CoV-2 testing was able to commence, several significant challenges were overcome by combining the expertise of our global teams with the local knowledge and support of the respective Governments. Experts in logistics and program management were able to convert three empty facilities with no pre-existing laboratory infrastructure into fully functional clinical testing laboratories within eight weeks. Our assay manufacturing capacity was majorly expanded to accommodate the requirements of SARS-CoV-2 testing, with all three facilities operating on automated platforms and utilizing chemistry with a dedicated secure supply chain. The final major challenge was rapid onboarding and training of staff for the facilities, and a year out, the two active facilities are currently employing over 600 individuals. Conclusion: To date the three facilities have performed over 12 million SARS-CoV-2 RT-PCR assays and SARS-CoV-2 testing will continue into 2022. The number of cases is again growing globally, and with the emergence of new variants and continual uncertainty about the impact on existing vaccines, there is an ongoing requirement for this scale of testing. From the experience of the SARS-CoV-2 global pandemic, the benefits of industry and government collaboration or the public has become much clearer, including greater access to large-scale testing options, significant reductions in time-to-testing and reporting and the rapid deployment of modern, cutting edge technology in diagnostic and monitoring programmes and eventually reduced costs to health services from mass-production. Ultimately the longevity of the individual testing facilities is unclear, but the future of large-scale clinical testing has changed forever and the legacy of this is the clear benefit to everybody when industry and governments work together to provide the public high quality and reliable testing operations. | Genet Med | 2022 | | CORD-19 |
| 4661 | eP488: Patient-centric adaptations for pheNIX clinical trial evaluating HMI-102 gene therapy in adults with PKU in the era of COVID-19 | Genet Med | 2022 | | CORD-19 |
| 4662 | eP325: Medically actionable DNA variation from the GENCOV COVID-19 Genome Sequencing Study | Genet Med | 2022 | | CORD-19 |
| 4663 | eP333: Tracking the emergence of SARS-CoV-2 variants of concern in vaccinated and unvaccinated patients | Genet Med | 2022 | | CORD-19 |
| 4664 | 338 ESKD Patient Experiences During the COVID-19 Pandemic: A Survey Study | Am J Kidney Dis | 2022 | | CORD-19 |
| 4665 | 298 Impact of COVID-19 Pandemic on Mental Health and Quality of Healthcare: Findings From the Joslin COVID-19 Study | Am J Kidney Dis | 2022 | | CORD-19 |
| 4666 | 333 Effect of COVID-19 Vaccination Drive on COVID-19 Outcomes in Urban Dialysis Centers | Am J Kidney Dis | 2022 | | CORD-19 |
| 4667 | 99 Pericardial Effusion: A Potential Late Complication of COVID-19 Infection | Am J Kidney Dis | 2022 | | CORD-19 |
| 4668 | 200 Stress and Adherence During the COVID-19 Pandemic in an Inner-City Population of Dialysis Patients: Relationship to Age | Am J Kidney Dis | 2022 | | CORD-19 |
| 4669 | 191 Factors Affecting Decision to Receive the COVID-19 Vaccine in Inner-City Dialysis Patients | Am J Kidney Dis | 2022 | | CORD-19 |
| 4670 | 286 Development of an Intervention to Facilitate Care for Latinx Individuals with Early Kidney Disease | Am J Kidney Dis | 2022 | | CORD-19 |
| 4671 | 282 Preoperative Assessment of GFR With Race-Based Versus Non-Race-Based GFR Calculators Prior to Nephrectomy for Renal Carcinoma | Am J Kidney Dis | 2022 | | CORD-19 |
| 4672 | 326 KDQOL Survey Scores in Dialysis Patients Decrease Following the First Year of the COVID-19 Pandemic With Concurrent Changes in Patient Adherence | Am J Kidney Dis | 2022 | | CORD-19 |
| 4673 | 316 Symptomatic Renal Infarct Secondary to COVID-19 Infection and Concomitantly Positive Antiphospholipid Antibody | Am J Kidney Dis | 2022 | | CORD-19 |
| 4674 | 156 COVID-19 Associated Nephrotic Syndrome | Am J Kidney Dis | 2022 | | CORD-19 |
| 4675 | 217 Is it Idiopathic Nodular Glomerulosclerosis or Diabetic Glomerulosclerosis? | Am J Kidney Dis | 2022 | | CORD-19 |
| 4676 | 218 Azole induced Pseudo Hyperaldosteronism With Therapeutic Levels of Posaconazole | Am J Kidney Dis | 2022 | | CORD-19 |
| 4677 | 214 Knowledge Gaps Regarding Chronic Kidney Disease and Diabetes in a Population of Inner-City Dialysis Patients | Am J Kidney Dis | 2022 | | CORD-19 |
| 4678 | 31 De Novo Class IV+V Lupus Nephritis After the BNT162b2 COVID-19 Vaccine | Am J Kidney Dis | 2022 | | CORD-19 |
| 4679 | 216 Acute Kidney Injury Associated With Anaplasmosis | Am J Kidney Dis | 2022 | | CORD-19 |
| 4680 | 219 Racial Differences and Outcomes in ESRD Patients Primarily Hospitalized With Empyema | Am J Kidney Dis | 2022 | | CORD-19 |
| 4681 | 337 Relapse of Membranous Nephropathy and Renal Sarcoidosis Following Exposure to SARS-CoV-2 Vaccine (Johnson & Johnson) | Am J Kidney Dis | 2022 | | CORD-19 |
| 4682 | 185 The Grid Course Facilitates Nutritional Education and Medical Nutrition Therapy for Patients With Chronic Kidney Disease | Am J Kidney Dis | 2022 | | CORD-19 |
| 4683 | 213 De novo IgA Nephropathy Following mRNA COVID-19 Vaccine | Am J Kidney Dis | 2022 | | CORD-19 |
| 4684 | 280 CKD and Rapid Kidney Function Decline During the COVID-19 Pandemic | Am J Kidney Dis | 2022 | | CORD-19 |
| 4685 | 212 Change in Food Purchasing Patterns and Increased Reliance on Support Programs During the COVID-19 Pandemic in Inner-City Dialysis Patients | Am J Kidney Dis | 2022 | | CORD-19 |
| 4686 | 181 Scleroderma Renal Crisis and COVID-Is There an Association? | Am J Kidney Dis | 2022 | | CORD-19 |
| 4687 | 182 A Terrible Trip: Tubulointerstitial Nephritis and Uveitis Syndrome Triggered by Psilocybe Mushroom Ingestion | Am J Kidney Dis | 2022 | | CORD-19 |
| 4688 | 288 Minimal Change Disease Relapse After SARS-CoV-2 Booster Vaccine | Am J Kidney Dis | 2022 | | CORD-19 |
| 4689 | 120 Seronegative Full-House Immune Complex Glomerulonephritis Post-mRNA COVID-19 Vaccination | Am J Kidney Dis | 2022 | | CORD-19 |
| 4690 | 183 A Pauci-Immune Crescentic Glomerulonephritis With ANCA-Associated Vasculitis; Prompt Diagnosis for a Favorable Outcome | Am J Kidney Dis | 2022 | | CORD-19 |
| 4691 | 285 Non-Emergent Medical Transportation Coordination for On-Time Treatments Among Hemodialysis Patients | Am J Kidney Dis | 2022 | | CORD-19 |
| 4692 | 383 SLE After SARS-COV-2 Infection | Am J Kidney Dis | 2022 | | CORD-19 |
| 4693 | 184 Recurrent UTIs Among CKD Patients: What's Behind Frequent Recurrences. Clinical Experience of One Nephrologist | Am J Kidney Dis | 2022 | | CORD-19 |
| 4694 | 100 Transplant Graft TMA Injury post-COVID-19 Vaccination | Am J Kidney Dis | 2022 | | CORD-19 |
| 4695 | 2 Renal Function Dynamics Among Mechanically Ventilated Patients With Acute Kidney Injury (AKI) And COVID-19 Pneumonia | Am J Kidney Dis | 2022 | | CORD-19 |
| 4696 | 215 A Case of Calcific Uremic Arteriolopathy With Severe Secondary Hyperparathyroidism, How High Is High? | Am J Kidney Dis | 2022 | | CORD-19 |
| 4697 | How to Talk to Myself: Optimal Implementation for Developing Fluency in EFL Speaking Through Soliloquizing “Soliloquizing” refers to the self-talk practice of a language learner through verbalizing thoughts using their target language. Through years of research, scholars have maintained that soliloquizing has the potential to promote language learners’ oral fluency in unscripted speech; nevertheless, empirical validation of soliloquizing has yet to be confirmed. The aims of the current study were two-fold: (1) to empirically establish the pedagogical efficacy of soliloquizing for promoting fluency in unscripted speech and to explore the most desirable implementation setting for this practice; and 2) to delve into second-language (L2) learners’ perceived attitudes towards and experience of soliloquizing. A total of 28 EFL college students with CEFR B1 English proficiency participated in a 4-week soliloquizing treatment under four conditions, i.e., [+ / − time pressure] × [+ / − restriction of fillers]. This L2 learners’ fluency, gleaned from the measure of pruned speech rate, was analyzed using paired sample t-tests and two-way ANOVA, while their attitudes were further investigated using questionnaires and interviews. This study showed that soliloquizing significantly enhanced EFL learners’ speaking fluency and attitude, and that an optimal soliloquizing setting was the one implemented with increasing time constraint. Based on the obtained quantitative and qualitative findings, desirable soliloquizing implementation settings are discussed. | N/A | 2022 | | CORD-19 |
| 4698 | SARS-CoV-2 Pneumonia, Acute Pulmonary Infarction Secondary to Acute Pulmonary Embolism, Secondary Spontaneous Pneumothorax and Subacute Invasive Pulmonary Aspergillosis: Are They Related to Each Other? | N/A | 2022 | | CORD-19 |
| 4699 | Consumers' dining behaviors during the COVID-19 pandemic: An Application of the Protection Motivation Theory and the Safety Signal Framework With the long-lasting impacts of the COVID-19 pandemic, it is critically important that restaurateurs understand predictors of consumers' dining behaviors to better foster strategies to recover their revenue during the re-opening stage. Based on the safety signal framework and the Protection Motivation Theory, this study developed and tested a model investigating the combined effects of restaurateurs' measures and consumers' protective motivations on their dine-out frequencies and dine-in likelihoods. Consistent with propositions of the Protection Motivation Theory, the results confirmed that both the threat and coping appraisals influenced consumers’ dining behaviors. The coping appraisal process is affected by “access to servicescape,” “servicescape,” and “communication.” Additionally, the results of the gap analysis revealed four safety signaling strategies perceived as effective by consumers but with a low implementation rate in the restaurant industry. Theoretical and practical implications were provided to restaurateurs. | N/A | 2022 | | CORD-19 |
| 4700 | Comprehensive Review on Applications of Surfactants in Vaccine Formulation, Therapeutic and Cosmetic Pharmacy and Prevention of Pulmonary Failure due to COVID-19 Our world is under serious threat of environmental degradation, climate change and in association with this the out breaks of diseases as pandemics. The devastating impact of the very recent COVID-19, The sharp increase in cases of Cancer, Pulmonary failure, Heart health has triggered questions for the sustainable development of pharmaceutical and medical sciences. In the search of inclusive and effective strategies to meet today’s demand, improvised methodologies and alternative green chemical, bio-based precursors are being introduced by scientists around the globe. In this extensive review we have presented the potentiality and Realtime applications of both synthetic and bio-based surfactants in bio-medical and pharmaceutical fields. For their excellent unique amphoteric nature and ability to solubilise in both organic and inorganic drugs, surfactants are one of the most potential candidates for bio-medicinal fields such as dermatology, drug delivery, anticancer treatment, surfactant therapy, vaccine formulation, personal hygiene care and many more. The self-assembly property of surfactants is a very powerful function for drug delivery systems that increases the bio-availability of the poorly aqueous soluble pharmaceutical products by influencing their solubility. Over the decades many researchers have reported the antimicrobial, anti-adhesive, antibiofilm, anti-inflammatory, antioxidant activities of surfactants regarding its utility in medicinal purposes. In some reports surfactants are found to have spermicidal and laxative activity too. This comprehensive report is targeted to enlighten the versatile applications of Surfactants in drug delivery, vaccine formulation, Cancer Treatment, Therapeutic and cosmetic Pharmaceutical Sciences and prevention of pulmonary failure due to COVID-19. | N/A | 2022 | | CORD-19 |
